Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $183.70 USD
Change Today +2.20 / 1.21%
Volume 548.2K
BCR On Other Exchanges
As of 8:04 PM 02/12/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

730 Central Avenue

Murray Hill, NJ 07974

United States

Phone: 908-277-8000

Fax: 908-277-8412

C. R. Bard, Inc., together with its subsidiaries, engages in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The company sells a range of products to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities. Products The company offers its products in four major product group categories: vascular, urology, oncology and surgical specialties. The company also has a product group of other products. Vascular Products The company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. These products include percutaneous transluminal angioplasty (PTA) catheters, chronic total occlusion (CTO) catheters, guidewires, fabrics, meshes, introducers and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters. The company’s Ultraverse and VascuTrak PTA catheters and Crosser CTO catheter give Bard one of the broadest offerings in the small-vessel segment of the PVD market. The company’s line of peripheral vascular stents, covered stents and vascular grafts includes the Flair AV (arterial venous) Access Stent Graft, E·Luminexx and LifeStar Iliac Stents, and the LifeStent family of stents approved for use in the superficial femoral and proximal popliteal arteries. Its vena cava filters product line includes devices that can be either permanently implanted or retrieved after the threat of blood clots traveling from the lower extremities to a patient’s lungs has passed. The company offers a portfolio of automatic core needle biopsy devices, including MaxCore and Magnum, as well as the Mission lightweight semi-automatic biopsy device. Its Vacora and Finesse devices combine the benefits of a vacuum-assisted biopsy technology with a portable, self-contained needle system for the diagnosis of breast tumors. The company offers various products across the percutaneous breast biopsy and tissue marker segments. The EnCor and EnCor Enspire breast biopsy systems allow for ultrasound-, stereotactic- and MRI-guided breast biopsy procedures, and its breast tissue markers include the SenoMark, StarchMark and Gel Mark product lines. Urology Products The company’s urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its Foley catheters include the infection control Foley catheter (Bardex I.C. Foley catheter), which reduce the rate of urinary tract infections. In 2013, the company acquired Rochester Medical Corporation and its line of intermittent self-catheters and male external catheters. Other products include fecal incontinence products; brachytherapy devices and radioactive seeds used to treat prostate cancer; intermittent urinary drainage catheters, urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; and surgical slings and pelvic floor repair products for women’s health. The company markets the proprietary line of StatLock catheter stabilization devices, which are used primarily to secure peripheral intravenous catheters, thereby reducing restarts and other complications. These devices are also used to secure many other types of catheters sold by Bard and other companies, including Foley catheters. In addition, the company markets the Arctic Sun system with proprietary ArcticGel pads providing therapy for patients requiring Targeted Temperature Management. Oncology Products The company’s oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. These include specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters and enteral feeding devices. The company’s specialty vascular access products are used primarily for chemotherapy. The company’s PowerPICC catheters and Powe

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCR:US $183.70 USD +2.20

BCR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Coloplast A/S kr489.80 DKK +4.80
Edwards Lifesciences Corp $81.04 USD +2.00
Endo International PLC $50.09 USD +1.60
Smith & Nephew PLC 1,065 GBp +14.00
Terumo Corp ¥3,695 JPY -125.00
View Industry Companies

Industry Analysis


Industry Average

Valuation BCR Industry Range
Price/Earnings 100.0x
Price/Sales 4.0x
Price/Book 9.2x
Price/Cash Flow 100.2x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CR BARD INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at